Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Orotic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.63 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.55 |
| ▸ | GPR84 | Q9NQS5 | 4/20 | 0.44 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | YTHDF3 | Q7Z739 | 1/20 | 0.36 |
| ▸ | YTHDF1 | Q9BYJ9 | 1/20 | 0.36 |
| ▸ | YTHDF2 | Q9Y5A9 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 2/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Orotic Acid SCHEMBL896843 | 0.96 | LMNA (0.63) | LMNAALDH1A1CYP1A2GPR84CA1 | |
| Orotic Acid SCHEMBL366202 | 0.96 | LMNA (0.63) | LMNAALDH1A1CYP1A2GPR84CA1 | |
| Orotic Acid SCHEMBL422601 | 0.96 | LMNA (0.63) | LMNAALDH1A1CYP1A2GPR84CA1 | |
| Orotic Acid SCHEMBL161884 | 0.96 | LMNA (0.63) | LMNAALDH1A1CYP1A2GPR84CA1 | |
| Orotic Acid SCHEMBL11903508 | 0.96 | ALDH1A1 (0.63) | LMNAALDH1A1CYP1A2GPR84CA1 | |
| Orotic Acid SCHEMBL23859826 | 0.96 | LMNA (0.63) | LMNAALDH1A1CYP1A2GPR84CA1 | |
| Orotic Acid SCHEMBL1854526 | 0.96 | LMNA (0.63) | LMNAALDH1A1CYP1A2GPR84CA1 | |
| Orotic Acid SCHEMBL5148012 | 0.96 | LMNA (0.63) | LMNAALDH1A1CYP1A2GPR84CA1 | |
| Orotic Acid SCHEMBL20518755 | 0.96 | LMNA (0.63) | LMNAALDH1A1CYP1A2GPR84CA1 | |
| Orotic Acid SCHEMBL1005000 | 0.96 | LMNA (0.63) | LMNAALDH1A1CYP1A2GPR84CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 728 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12527813-B2 | Methods to stabilize and reverse atherosclerotic lesions by sulfated polysaccharides | CALROY HEALTH SCIENCES, LLC (US) | 2026-01-20 | — | — | US | claimed |
| US-20250367169-A1 | FORMULATIONS FOR PERSONALIZED METHODS OF TREATMENT | FAETH THERAPEUTICS INC (US) | 2025-12-04 | — | — | US | claimed |
| CN-119874627-A | Preparation method of magnesium orotate | 郑州瑞普生物工程有限公司 | 2025-04-25 | — | — | CN | claimed |
| CN-119798170-A | Preparation method of high-purity magnesium orotate | 宁波盈前科技有限公司 | 2025-04-11 | — | — | CN | claimed |
| US-12220402-B2 | Formulations for personalized methods of treatment | FAETH THERAPEUTICS, INC. (US) | 2025-02-11 | — | — | US | claimed |
| US-20240409547-A1 | Solid Forms of Upadacitinib | THE BANK OF NOVA SCOTIA (CA) | 2024-12-12 | — | — | US | claimed |
| EP-4225318-B1 | MAGNESIUM OROTATE IN COMBINATION WITH FOLIC ACID FOR THE TREATMENT OF DEMENTIA | WOERWAG PHARMA GMBH & CO KG (DE) | 2024-11-13 | — | — | EP | claimed |
| US-20240261286-A1 | BIOFACTORS FOR THE TREATMENT AND PROPHYLAXIS OF DEMENTIA | Wörwag Pharma GmbH & Co.KG (DE) | 2024-08-08 | — | — | US | claimed |
| WO-2024155274-A1 | FORMULATION BASES COMPRISING HYALURONIC ACID AND FORMULATIONS OF SAME | DT IP HOLDINGS I, LLC (US) | 2024-07-25 | — | — | WO | claimed |
| EP-4351609-A1 | ORAL COMPOSITION FOR THE TREATMENT AND/OR PREVENTION OF DISORDERS ASSOCIATED WITH MENOPAUSE | Pizeta Pharma S.P.A. (IT) | 2024-04-17 | — | — | EP | claimed |
| US-6620836-B1 | Administering melatonin and magnesium compound | PATRICK JAY (US) | 2003-09-16 | — | — | US | claimed |
| WO-2003049730-A1 | TREATMENT OF STATIN SIDE EFFECTS USING URIDINE DERIVATIVES | MAGRAL LIMITED (AU) | 2003-06-19 | — | — | WO | claimed |
| US-20030099724-A1 | Compounds for prevention of diabetic retinopathy | TURNER OLIVER E (US) | 2003-05-29 | — | — | US | claimed |
| WO-2002043721-A1 | TREATMENT OF STATIN SIDE EFFECTS | CENTRE FOR MOLECULAR BIOLOGY AND MEDICINE (AU) | 2002-06-06 | — | — | WO | claimed |
| US-6042849-A | FOR TREATMENT OF CONDITIONS ASSOCIATED WITH THE CONSTRICTION OF SMALL BLOOD VESSELS SUCH AS ATHEROGENESIS, HEART ATTACK, STROKE, HYPERTENSION, GLAUCOMA, MIGRAINE, HYPERTENSION OF PREGNANCY, AND DIABETES MELLITUS | CHRONORX, LLC (US) | 2000-03-28 | — | — | US | claimed |
| US-5849338-A | Unit dosage forms for treatment of vasoconstriction and related conditions | CHRONORX LLC (US) | 1998-12-15 | — | — | US | claimed |
| WO-1997037670-A1 | UNIT DOSAGE FORMS, CONTAINING MAGNESIUM, VITAMIN C, VITAMIN E, FOLATE AND SELENIUM, FOR TREATMENT OF VASOCONSTRICTION AND RELATED CONDITIONS | CHRONORX, LLC (US) | 1997-10-16 | — | — | WO | claimed |
| US-4738856-A | Beverage and method for making a beverage for the nutritional supplementation of calcium in humans | NUTRITION TECHNOLOGIES, INC. (US) | 1988-04-19 | — | — | US | claimed |
| EP-0246177-A2 | A beverage and method for making a beverage for the nutritional supplementation of calcium in humans | Clark, George H. (US) | 1987-11-19 | — | — | EP | claimed |
| EP-0202106-A2 | A beverage and method of making a beverage for the replacement of body fluids and electrolytes | Clark, George H. (US) | 1986-11-20 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12527813-B2 | Methods to stabilize and reverse atherosclerotic lesions by sulfated polysaccharides | RPS4Y1, PF4, PKD1 | LMNA 2973/4885ALDH1A1 3564/4885CYP1A2 3803/4885 |
| US-20240261286-A1 | BIOFACTORS FOR THE TREATMENT AND PROPHYLAXIS OF DEMENTIA | OAT, OTC, MTHFD1 | LMNA 2642/4885ALDH1A1 1326/4885CYP1A2 489/4885 |
| US-20240409547-A1 | Solid Forms of Upadacitinib | AURKC, APC, CHUK | LMNA 4652/4885ALDH1A1 1665/4885CYP1A2 832/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.